Accessibility Information

Users of assistive technologies such as screen readers should use the following link to activate Accessibility Mode before continuing: Learn more and Activate accessibility mode.

A -- Regional Biocontainment Laboratories (RBL) and National Biocontainment Laboratories (NBL)

Solicitation Number: BAA-NIH-NIAID-NCRR-DMID-03-36
Agency: Department of Health and Human Services
Office: National Institutes of Health
Location: National Institute of Allergy and Infectious Diseases
  • Print
:
BAA-NIH-NIAID-NCRR-DMID-03-36
:
Solicitation
:
Added: October 2, 2002 Modified: November 5, 2002Track Changes
This announcement replaces the presolicitation notice posted on October 2, that was accidentally deleted from the FedBizOpps on 11/5/02.

The Department of Health and Human Services (DHHS), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) and the National Center for Research Resources (NCRR), are collaborating on the subject Broad Agency Announcement. The NIAID and NCRR encourages the submission of grant applications and/or contract proposals for the establishment of Regional and National Biocontainment Laboratories, respectively, in order to further the research capabilities of the Division of Microbiology and Infectious Diseases (DMID), NIAID, to conduct research on Category A, B, and C priority pathogens that are considered to be of significant research importance. The list of pathogens is provided at the following weblink: (http://www.niaid.nih.gov/dmid/bioterrorism/bandc_priority.htm). Only domestic (U.S.), non-Federal, public or private non-profit organizations that support biomedical research are eligible to apply. Awards under this program are contingent on availability of appropriated funds and NIAID appropriations authority provided at the discretion of Congress. In February of 2002, the NIAID developed a strategic plan for biodefense research in consultation with a Blue Ribbon Panel to accomplish short- and long-term goals aimed at protection of the United States and the world population against attacks by these agents. The NIAID strategic plan emphasizes both basic research and the application of the basic research to the development of products such as diagnostics, therapeutics, and vaccines. The Biocontainment Laboratories being solicited through this Broad Agency Announcement (BAA) will be an integral part of the biodefense research agenda of the NIAID. This BAA will consist of two parts: Part A - Regional Biocontainment Laboratories (RBLs) to be awarded as grants and Part B - National Biocontainment Laboratories (NBLs) to be awarded as contracts. PART A - RBLs: The overall planned objective of the RBL construction program is to provide funding to design, build, renovate, certify and install fixed equipment into state-of-the-art BSL-3 biocontainment laboratories and the necessary associated BSL-2 labs, animal facilities, and research support space. RBLs will be required to preferentially support the research activities of NIAID Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research (RCE), as well as other NIAID funded biodefense and emerging infectious diseases research. RBLs will be part of the NIAID RCE Biodefense Network and will serve as a regional resource for research institutions in the region. In addition, RBLs will be required to be available and prepared to assist national, state, and local public health efforts in the event of a bioterrorism emergency. PART B - NBLs: The overall objective of the NBL construction program is to provide funding to design, build, and certify comprehensive, state-of-the-art BSL-4 biocontainment laboratories and the necessary associated BSL-3 labs, BSL-2 labs, animal facilities, and research support space. NBLs will serve as a national resource for efforts in conducting clinical and laboratory (in vitro and in vivo) research and testing on hazardous biological agents in support of the NIAID?s Biodefense Agenda. NBLs will be required to preferentially support the research activities of NIAID Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research (RCE), as well as other NIAID funded biodefense research. NBLs will be part of the NIAID RCE Biodefense Network and will serve as a national resource for research. In addition, NBLs must be available and prepared to assist national, state, and local public health efforts in the event of a bioterrorism emergency. BAA-NIH-NIAID-NCRR-DMID-03-36 will be available electronically on or about October 15, 2002, and may be accessed through the NIAID Contract Management Branch (CMB) home page at http://www.niaid.nih.gov/contract. Any responsible offeror may submit a proposal that will be considered by the Government. This announcement does not commit the Government to make an award. No collect calls will be accepted. No facsimile transmission will be accepted. The Point of Contact for Grant Applications for RBLs is Mary Kirker, Grants Manager Officer, Phone 301-402-6400, Email mk35h@nih.gov, Fax 301-480-3780 and Linda Shaw, Grants Management Specialist, Phone 301-402-6611, Fax 301-480-3780, Email ls15k@nih.gov. For questions regarding the NBLs, please contact the individuals identified below.

Please consult the list of document viewers if you cannot open a file.

Solicitation 1

Type:
Solicitation
Posted Date:
November 6, 2002
20021106063651.zip (525.88 Kb)
Description: All Files

Amendment 1

Type:
Mod/Amendment
Posted Date:
February 4, 2003
Description: All Files

Amendment 2

Type:
Mod/Amendment
Posted Date:
February 4, 2003
Description: All Files
:
Department of Health and Human Services, National Institutes of Health, National Institutes of Allergy and Infectious Diseases, Contract Management Branch 6700 B Rockledge Room 2230 MSC7612, Bethesda, MD, 20892-7605
:
Barbara Shadrick, Senior Contracting Officer, Phone 301-496-7288, Fax 301-480-5253, Email bs92y@nih.gov - Kristen Mistichelli, Contract Specialist, Phone 301-496-0384, Fax 301-480-5253, Email KMistiche@niaid.nih.gov